Entera
Business Services · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hadassah Bio Park Fl 5, Jerusalem, Jerus...Phone Number
+97225327151Website
www.enterabio.comRevenue
-Stock Symbol
ENTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Entera
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product candidates, EB613 for the treatment of high risk, post-menopausal osteoporosis and EB612 for the treatment of hypoparathyroidism, are in clinical development.Explore more
Entera Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Entera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Entera had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Entera launches new products
Earning: See what the market has to say on Entera recently announced quarterly report
Check if Entera has recently received funding, and reach out quickly before it becomes old news!
Entera, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Entera is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Entera
Funding: Get notified immidiatlly once Entera has new funding data
Recommended Actions
Find VP level buyers at Entera
Find more new buyers
Company Profile Activity
Activity Insights
Entera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Entera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Entera.
Entera financials insights
Gather financial insights about Entera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$7.5M
2026
Stock/Share Issuance
$275M
Entera Tech Stack
A closer look at the technologies used by Entera
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Events
Funding
Funding
Earnings
Earnings, Finance
Executive Move
Executive Moves, Board of Directors
Entera News & Media
Correction: Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences:Entera to Participate in Upcoming Fall Investor Conferences
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences:Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and NovartisEntera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Entera
Sign Up For FreeTo access detailed company insights
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product ca... Read More
